(Q39925893)

English

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

scientific article published on 25 November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Josep Tabernero Caturla

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Fortunato Ciardiello

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Francisco J Ramos

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

F Rivera

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

E Rodriguez-Braun

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

E Martinelli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M E Vega-Villegas

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Roselló

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Liebscher

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

O Kisker

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

T Macarulla

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A Cervantes

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

J Baselga

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

25 November 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1537-1545

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP549

21 January 2018

Identifiers

10.1093/ANNONC/MDP549

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19940007%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39925893&oldid=2143926915"